Onconova Therapeutics Stock News

Marshall Wace LLP acquired a new stake in Onconova Therapeutics, Inc. (NASDAQ:ONTX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 24,345 shares of the biopharmaceutical companys stock, valued at approximately $169,000. Marshall Wace LLP owned approximately 0.15% of Onconova Therapeutics as of []

Onconova Therapeutics, Inc. (NASDAQ:ONTX)s share price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $5.22 and traded as low as $2.89. Onconova Therapeutics shares last traded at $3.00, with a volume of 405,714 shares changing hands. A number of analysts []

Geode Capital Management LLC lessened its holdings in Onconova Therapeutics, Inc. (NASDAQ:ONTX) by 93.1% during the second quarter, HoldingsChannel reports. The firm owned 142,980 shares of the biopharmaceutical companys stock after selling 1,923,647 shares during the quarter. Geode Capital Management LLCs holdings in Onconova Therapeutics were worth $990,000 at the end of the most recent []

Onconova Therapeutics Inc. (NASDAQ:ONTX) price on Friday, November 19, rose 0.64% above its previous days close as an upside momentum from buyers pushed the stocks value to $3.16. A look at the stocks price movement, the close in the last trading session was $3.14, moving within a range at $3.10 and $3.27. The beta value Is Onconova Therapeutics Inc. (NASDAQ: ONTX) A Top Momentum Pick? Read More »

Onconova Therapeutics (NASDAQ:ONTX) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating the Zacks consensus estimate of ($0.33) by $0.11, MarketWatch Earnings reports. Onconova Therapeutics had a negative net margin of 8,294.27% and a negative return on equity of 74.01%. During the same period []

Onconova Therapeutics, Inc.'s (ONTX) CEO Steve Fruchtman on Q3 2021 Results - Earnings Call Transcript

Onconova Therapeutics (NASDAQ:ONTX) reported its Q3 earnings results on Thursday, November 11, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Onconova Therapeutics (NASDAQ:ONTX) is set to give its latest quarterly earnings report on Thursday, 2021-11-11. Here's what investors need to know before the announcement.

NEWTOWN, Pa., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel pro

Investors need to pay close attention to Onconova (ONTX) stock based on the movements in the options market lately.

Onconova Therapeutics Inc (NASDAQ: ONTX) has priced an underwritten public offering of 5 million shares at $4.20 for gross proceeds of $21 million. The offer price represents an almost 17% discount

NEWTOWN, Pa., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat

NEWTOWN, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat

Onconova (ONTX) is developing a combination of its rigosertib plus Bristol-Myers' Opdivo for treating cancer with solid tumors. Preliminary data from the phase I/II study demonstrates disease control

The stock price of Onconova Therapeutics Inc (NASDAQ: ONTX) is trading at over 25% during intraday trading today. This is why it happened.